TraceLink expands European HQ to accommodate projected 207% EU employee growth in 2017
Extends EMEA sales team with addition of two new regional sales leaders in DACH and Southern Europe regions.
TraceLink will relocate its European headquarters to a larger, newly renovated office space in Uxbridge, UK. The move will accommodate the company’s projected 207% year-over-year increase in EU staff growth for 2017.
To help the life sciences industry meet global regulatory deadlines for pharmaceutical track and trace and accommodate its 658% growth in EMEA new sales bookings for Q1 2017, the company is expanding its overall European team by hiring 55 new EU-based employees in sales, services, marketing and administration during 2017.
As part of its recruitment drive, the company has added two regional EU sales leaders, deepening its pan-European presence to develop localised TraceLink teams dedicated to serving the life sciences industry in specific regions. Leading the DACH (Germany, Austria and Switzerland) region as TraceLink Vice President, Sales, Manfred Voglmaier, a native resident of Germany, brings over 25 years of industry experience in technology and life sciences, and comes from Systech International as the former Senior Director of EMEA Sales. Heading up Southern Europe, Renaud Delcroix has joined TraceLink as Vice President, Sales for the region, bringing strong expertise in cultivating international business development teams across industry verticals.
“By 2020, over 80% of the world’s prescription drugs will be covered by track and trace laws; a challenge that involves massive amounts of data and a complex web of supply chain partners. Expanding our presence in Europe is a natural step due to the urgent demand we’ve seen from the region for our proven solution in meeting EU Falsified Medicines Directive (FMD) requirements,” said Shabbir Dahod, president and CEO, TraceLink. “As part of our $70 million investment in 2017 into the pharmaceutical track and trace industry, we are building localised support and services for our customers who have mission-critical operations across 24 countries to best accommodate our rapid-growing global customer base.”
The development of the European team will be focused on continuing to build regional and native expertise in these areas, and expanding the 15 languages already spoken by the current TraceLink services team in EMEA. Worldwide, TraceLink expects to have nearly 400 employees by the end of 2017, a 68% year-over-year increase in global employee growth.
Later this year, TraceLink will offer general availability to its European Union (EU) hosted Life Sciences Cloud, furthering its commitment to serving its EU-based and global customers by enabling data residency in both the EU and US. By utilising TraceLink’s unique network-tenant platform approach, global customers will be able to significantly reduce the time, cost and risk of achieving regulatory compliance for global requirements, including the EU FMD, and eliminate the need to verify and certify point-to-point connections to each government system.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance